How Analysts Feel About Biogen Inc. (NASDAQ:BIIB)?

Biogen Inc. (NASDAQ:BIIB) Logo
Investors sentiment decreased to 0.7 in 2019 Q2. Its down 0.18, from 0.88 in 2019Q1. It turned negative, as 82 investors sold Biogen Inc. shares while 316 reduced holdings. 78 funds opened positions while 202 raised stakes. 153.48 million shares or 6.01% less from 163.29 million shares in 2019Q1 were reported.
Japan-based Nomura Asset Mngmt Ltd has invested 0.14% in Biogen Inc. (NASDAQ:BIIB). Aviva Plc has invested 0.12% in Biogen Inc. (NASDAQ:BIIB). Guardian Life Ins Of America holds 0.02% or 568 shares. Cleararc Cap Inc holds 2,634 shares. Destination Wealth Management reported 0% stake. Shelton Cap has invested 0.28% in Biogen Inc. (NASDAQ:BIIB). Pzena Investment Mngmt Ltd Liability Company reported 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Cambridge Investment Rech Advsr has 5,683 shares for 0.01% of their portfolio. Manchester Cap Mgmt Ltd Liability Company reported 0.06% in Biogen Inc. (NASDAQ:BIIB). Mutual Of America Cap Ltd Liability Corporation stated it has 0.09% in Biogen Inc. (NASDAQ:BIIB). Hm Payson And Co holds 0.01% in Biogen Inc. (NASDAQ:BIIB) or 989 shares. Globeflex Ltd Partnership holds 24 shares or 0% of its portfolio. Jane Street Group Limited Com holds 0.03% or 66,879 shares. 5,119 are owned by Btim. Omers Administration Corp holds 0.07% or 26,500 shares.

Since April 30, 2019, it had 1 buy, and 0 sales for $27.21 million activity.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 19 analysts covering Biogen Inc (NASDAQ:BIIB), 6 have Buy rating, 1 Sell and 12 Hold. Therefore 32% are positive. Biogen Inc has $416 highest and $19800 lowest target. $270.84’s average target is 14.16% above currents $237.24 stock price. Biogen Inc had 31 analyst reports since March 20, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, March 20 by Mizuho. Piper Jaffray downgraded the stock to “Neutral” rating in Friday, June 28 report. The company was maintained on Thursday, March 21 by Cowen & Co. The firm earned “Hold” rating on Thursday, March 21 by Barclays Capital. On Thursday, March 21 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The company was downgraded on Thursday, March 21 by Bank of America. The company was maintained on Monday, March 25 by H.C. Wainwright. The rating was maintained by BMO Capital Markets with “Hold” on Friday, March 22. Oppenheimer maintained the stock with “Buy” rating in Thursday, March 21 report. Nomura maintained it with “Buy” rating and $320 target in Thursday, March 21 report. Below is a list of Biogen Inc. (NASDAQ:BIIB) latest ratings and price target changes.

24/07/2019 Broker: Canaccord Genuity Rating: Hold Old Target: $275.0000 New Target: $285.0000 Maintain
28/06/2019 Broker: Piper Jaffray Old Rating: Overweight New Rating: Neutral Old Target: $280.0000 New Target: $250.0000 Downgrade
23/05/2019 Broker: Wedbush Rating: Neutral New Target: $231.0000 Initiates Coverage On
21/05/2019 Broker: Credit Suisse Rating: Underperform New Target: $198.0000 Initiates Coverage On
09/05/2019 Broker: Barclays Capital Rating: Equal-Weight Old Target: $250.0000 New Target: $245.0000 Maintain
26/03/2019 Broker: Raymond James Rating: Buy New Target: $280 Maintain
25/03/2019 Broker: RBC Capital Markets Rating: Hold New Target: $236 Maintain
25/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $300 Maintain
22/03/2019 Broker: Leerink Swann Rating: Hold Maintain
21/03/2019 Broker: Barclays Capital Rating: Hold New Target: $250 Maintain

The stock increased 2.12% or $4.93 during the last trading session, reaching $237.24. About 1.10M shares traded. Biogen Inc. (NASDAQ:BIIB) has declined 28.25% since September 13, 2018 and is downtrending. It has underperformed by 28.25% the S&P500.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $43.76 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 8.84 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Seekingalpha.com which released: “SMA STAT test now available at no charge – Seeking Alpha” on August 20, 2019, also Nasdaq.com with their article: “Are Investors Undervaluing Biogen (BIIB) Right Now? – Nasdaq” published on August 14, 2019, Nasdaq.com published: “Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat – Nasdaq” on July 23, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Assessing Impact Of Biogen (BIIB) News – Nasdaq” published on March 21, 2019 as well as Nasdaq.com‘s news article titled: “Insiders Buy the Holdings of MOAT ETF – Nasdaq” with publication date: September 03, 2019.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.